News und Analysen
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety
EQS-News: Immunic to Participate in Investor and Scientific Conferences in September
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
Uni-Bio Science Group Announces 2025 Interim Results
EQS-News: BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
EQS-News: Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sensorion Announces Its Participation In Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares